drugset / Trial / NCT01775137

Ext. Long-term Safety Study in CF Patients: Single Arm TIP

NCT01775137

Phase 4 Completed 45 enrolled Novartis Pharmaceuticals
Non-randomizedSingle-groupOpen-label

Summary

The purpose of this extension study is to collect additional 48 weeks of safety data from patients taking TIP who have completed the core study CTBM100C2401. The purpose of collecting second year safety data through this study is to obtain long-term (2 years) safety data of TIP.

Timeline

Start
2013-02
Primary completion
2014-11
Completion
2014-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Tobramycin Small molecule 112 mg Inhaled

Indications

No indication recorded.